Merck To Purchase Cidara At $221.50 Per Share In Major Pharma Deal

token_therapist · 2025-12-26T05:51:59+00:00

Merck has agreed to acquire Cidara Therapeutics for $9.2 billion to enhance its antiviral portfolio, focusing on influenza treatment. The acquisition centers on Cidara's promising candidate, CD388, which is in Phase 3 trials. Market reaction has been positive, with Cidara shares rising significantly.

token_therapist

2025-12-26 05:51:59

Abstract generation in progress

Merck has announced a definitive agreement to acquire Cidara Therapeutics, Inc. in an all-cash transaction valued at approximately $9.2 billion. Under the terms of the agreement, each share of Cidara will be purchased at $221.50, pending approval from a majority of Cidara’s shareholders through a tender offer process. The deal is anticipated to finalize during the first quarter of 2026, with accounting treatment classified as an asset acquisition.

The Strategic Rationale Behind The Acquisition

This acquisition represents Merck’s commitment to expand its antiviral portfolio, particularly in the influenza treatment space. By bringing Cidara into its fold, Merck gains access to innovative research and a promising clinical pipeline. Robert Davis, chairman and CEO of Merck, emphasized the company’s confidence in the transaction: “Cidara’s team has demonstrated exceptional progress, and we believe their lead asset will serve as a significant growth engine over the coming decade, delivering substantial returns to our shareholders.”

CD388: The Crown Jewel Of This Transaction

At the heart of this acquisition is CD388, Cidara’s flagship immunotherapy candidate. This compound combines a small molecule neuraminidase inhibitor with an Fc fragment of human antibody in a stable conjugate structure, creating a novel mechanism specifically engineered to combat both influenza A and B strains. The compound is actively progressing through the Phase 3 ANCHOR study, which is enrolling adult and adolescent participants at elevated risk for influenza-related complications.

Market Response And Deal Timeline

Trading activity on Friday reflected strong investor sentiment toward the acquisition, with Cidara shares surging 103% in pre-market trading. This substantial appreciation underscores market confidence in both the valuation and the strategic merit of the transaction. The deal structure requires Cidara shareholders to tender their shares, with closing expected in early 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.